N- (3- cyano- 4- methyl- 1H- indol- 7- yl)- 3- cyanobenzene- sulfonamide

04/01/2009 - "The aim of this study was to assess the population pharmacokinetics (PopPK) of the novel oral anti-cancer agent E7820. "
05/18/2021 - "However, at present no data is available on the effect of E7820 on osseous cells or skeletal malignancies. "
01/01/2016 - "Pre-clinically E7820 showed tumor anti-angiogenic effects in various tumor cell lines and xenograft mouse models. "
02/15/2004 - "Immunohistochemical analyses using anti-CD31 antibody showed that E7820 significantly reduced microvessel density in orthotopically implanted KP-1 tumor. "
02/15/2004 - "Moreover, E7820 significantly inhibited the growth of KP-1 and human colon tumor Colo320DM cells orthotopically implanted in the pancreas and cecum, respectively. "

05/18/2021 - "Currently the application of E7820 in the treatment of various malignancies including pancreas carcinoma and breast cancer is being investigated in pre-clinical and clinical trials. "

05/18/2021 - "Currently the application of E7820 in the treatment of various malignancies including pancreas carcinoma and breast cancer is being investigated in pre-clinical and clinical trials. "

11/01/2002 - "Oral administration of E7820 remarkably resulted in inhibition of tumor-induced angiogenesis in mouse dorsal air sac model, and tumor growth of human colorectal tumor cell lines (WiDr and LoVo) was inhibited in xenotransplanted model in mice. "
06/01/2019 - "Combining E7820 and chemotherapeutic agents to block the integrin α2β1/PI3K/AKT/Snail signaling pathway revealed dramatic enhanced tumor suppression and provided an innovative approach for clinical colorectal cancer treatment."
06/01/2019 - "Blocking the pathway by applying E7820 successfully reversed the type I collagen induced distant metastasis in colorectal cancer. "

05/18/2021 - "To transfer E7820 treatment to bone-related pathologies, as non-healing fractures, osteoporosis and bone cancer might therefore be beneficial. "